血立停胶囊对早孕大鼠RU486药流后NO、NOS表达的影响

目的:研究血立停胶囊对早孕大鼠RU486药物流产后的子宫平滑肌一氧化氮(NO)及一氧化氮合酶(NOS)水平变化的影响。方法:选择妊娠Wistar大鼠,随机分为5组,即对照组,米非司酮组,大剂量血立停组,小剂量血立停组,催产素组。于妊娠第7天,开始相应处理,妊娠第14天分别监测早孕大鼠RU486药物流产后的子宫平滑肌一氧化氮(NO)及一氧化氮合酶(NOS)水平后处死。结果:大剂量血立停可明显降低大鼠子宫肌组织匀浆中NO、NOS含量,与对照组比较差异有显著性(P<0.05)。结论:血立停胶囊可降低子宫肌组织匀浆中NO、NOS水平,从而起到对药物流产后阴道出血的治疗作用。     

离体子宫张力测定在药物生殖毒性研究中的应用

目的:建立药物生殖毒性研究中孕鼠离体子宫平滑肌张力的测定方法。方法:SD大鼠于妊娠第6~15天(GD6-15)给予受试物,在妊娠第20天(GD20)取子宫平滑肌,分别给予不同浓度缩宫素和硫酸镁溶液刺激,选择试验的最佳条件。在此基础上,测定不同剂量组孕鼠离体子宫平滑肌张力的变化情况,采用RM-6240BD多道生理信号采集处理系统分析数据,统计结果。结果:选择0.007 U/m L缩宫素、0.008 mol/m L硫酸镁为最佳刺激浓度。随着受试物剂量的增加,加入缩宫素后,各组妊娠子宫平滑肌的频率和张力均呈逐渐上升的趋势,而加入硫酸镁后,各剂量组妊娠子宫平滑肌的活动幅度、频率和张力均呈现降低的趋势,但各剂量组与溶媒对照组相比均未见明显差异(P0.05)。结论:本研究建立了孕鼠离体子宫平滑肌张力的测定方法,该方法可以更好的反映受试物对孕鼠子宫肌的毒性作用,更加全面的评价受试物的生殖毒性。     

痛血康胶囊对早孕大鼠不完全流产模型的治疗作用

目的：探讨痛血康胶囊治疗早孕SD大鼠不完全流产模型产后出血的疗效及作用机制。方法：1）受孕7 d予米非司酮和米索前列醇,造成早孕不完全流产模型,痛血康治疗7 d观察并记录SD大鼠离体子宫平滑肌活动情况及病理组织学改变。2）用小鼠尾尖取血法,观察痛血康对小鼠出凝血时间的影响。3）用小鼠耳廓肿胀和SD大鼠棉球肉芽肿两个模型,观察痛血康的抗炎作用。4）用皮下注射肾上腺素加冰水刺激所致SD大鼠血瘀模型,观察痛血康的活血化瘀作用。结果：痛血康能增强早孕不完全流产SD大鼠子宫平滑肌收缩强度,促进残存的胚囊组织排出;能降低血瘀模型SD大鼠全血和血浆黏度,缩短小鼠出凝血时间;对二甲苯所致小鼠耳廓肿胀和SD大鼠棉球肉芽肿有明显抑制作用。结论：痛血康在早孕SD大鼠中具有治疗产后出血的作用,可能与增强流产SD大鼠的子宫收缩强度、促进残留在宫腔的绒毛或蜕膜组织排出、缩短出凝血时间、抑制炎症等有关。     

大黄素对大鼠离体空肠平滑肌收缩的影响

目的：观察大黄素（emodin）对大鼠离体空肠平滑肌收缩功能的影响,并探讨其作用机制。方法：大鼠离体空肠标本随机分为7组（n=6）：对照组,大黄素剂量组（1,5,10,20μmol／L）,普萘洛尔（PRO）加大黄素组,格列苯脲（GLI）加大黄素组,NG-基-L厂精氨酸甲酯（1．NAME）加大黄素组,无钙K-H液对照组及无钙K-H液大黄素组。采用颈椎离断法处死大鼠并分离其空肠,将肠段标本与张力换能器相连并置于氧饱和的K-H液中。采用BL-420E＋生物信号采集处理系统记录大鼠空肠平滑肌的收缩张力（TE）,幅度（AM）和频率（FR）的影响。结果：①大黄素能使大鼠离体空肠平滑肌的收缩张力和幅度明显下降,且呈剂量依赖性（P〈0．05,P〈0．01）;对频率无明显影响。②普萘洛尔（P〈0．05）、格列苯脲（P〈0．01）可部分阻断大黄素对空肠平滑肌的抑制作用。③L．NAME对大黄素所引起的空肠平滑肌的抑制作用无影响。④氯化钙所引起的空肠平滑肌收缩可被大黄素所抑制（P〈0．01）。结论：大黄素能明显减弱大鼠离体空肠平滑肌的收缩张力和收缩幅度,对收缩频率无影响。这种作用可能是通过兴奋肾上腺素8受体、兴奋ATP敏感钾通道、阻断细胞膜上钙离子通道实现。     

离体子宫平滑肌测定方法的改进

目的:探索离体子宫平滑肌测定方法中,使用增氧泵通气取代混合氧为离体子宫平滑肌供氧的可行性。方法:采用RM-6240BD多道生理信号采集处理系统,观察营养液内通入混合氧、增氧泵通气及无通气对离体子宫平滑肌活动力的影响。结果:与营养液内通入混合氧相比,离体子宫平滑肌的活动力在混合氧组与增氧泵通气组间无统计学差异(P0.05),不通气组的频率和活动力均有统计学差异(P0.05或P0.01)。结论:可以使用增氧泵通气为离体子宫平滑肌供氧,既满足了供氧,同时也可促进营养液流动,使离体子宫与营养液充分接触。     

五加生化胶囊对药物流产出血模型大鼠的影响及机制研究

目的:观察五加生化胶囊对药物(米非司酮配伍米索前列醇)致流产出血大鼠模型的保护作用,并探讨其作用机制。方法:建立大鼠药物流产出血模型,分为正常组(K)、受孕对照组(KY)、模型组(M)和给药(G)组,观测大鼠子宫出血时间、出血量、子宫指数、子宫形态和血液流变学改变,采用放射免疫法、ELISA法、免疫组织化学法和IPP6.0图像分析系统对比观察了大鼠血清雌二醇(E2)、血浆层粘连蛋白(LM)和纤维连接蛋白(FN)含量变化,以及子宫组织中FN、LM和雌、孕激素受体(ER、PR)表达的变化。结果:与M组比较,G组药物流产出血大鼠子宫血量由0.40±0.15**mL减少到0.22±0.16#m L,出血时间由124.4±22.0**h减少到71.3±10.4##h,血清E2含量在第14天由22.47±6.37pg/mL到39.57±5.19##pg/mL,子宫ERα表达OD值由0.036±0.025**升高到0.208±0.072##和PR的表达OD值由0.043±0.023*升高到0.095±0.035#,血浆和子宫组织LM和FN水平降低,血液流变性得以改善。结论:五加生化胶囊具有减少药物流产出血大鼠子宫出血量和出血时间的作用,其作用机制主要为降低了血浆和子宫组织FN的含量,起到使残留的蜕膜组织顺利排出的目的,减少了残留蜕膜对子宫的刺激;提高血清中E2含量和子宫组织中ERα和PR的表达,同时改善了血液流变性,使受损子宫组织局部血液循环得到改善加速了受损子宫的恢复速度。     

姜黄素对小鼠离体十二指肠平滑肌舒缩活动的影响

目的:本研究采用小鼠离体十二指肠平滑肌观察姜黄素对胃肠道蠕动的影响,探讨其作用机制。方法:取小鼠离体十二指肠平滑肌条,放入37℃Krebs液浴槽中,通入95%氧气和5%二氧化碳混合气体,分组进行下列实验:对照组和分别加入10-40 M姜黄素组,测量记录十二指肠平滑肌的自主收缩变化;另取一组平滑肌条,分对照组、乙酰胆碱组、乙酰胆碱+姜黄素组、阿托品组、阿托品+姜黄素组,采用张力换能器连接多通道生理信号采集处理系统,测量比较十二指肠平滑肌舒缩的变化。结果:小鼠十二指肠平滑肌加入姜黄素孵育后,其自主收缩幅度有明显下降(P0.01),而且降低的幅度与姜黄素剂量相关;给与乙酰胆碱引起十二指肠收缩后,再加姜黄素孵育,十二指肠平滑肌的收缩幅度明显的下降(P0.01);给予阿托品引起小鼠平滑肌舒张后,再给予姜黄素孵育,平滑肌收缩幅度进一步降低。结论:姜黄素对小鼠离体十二指肠平滑肌具有直接舒张作用。     

化学药物对家兔离体小肠平滑肌电生理特性的影响

观察各种化学药物对家兔离体小肠各段平滑肌的作用,采用常规离体灌流的十二指肠、空肠及回肠平滑肌标本作舒缩运动实验,记录用药前后各段小肠平滑肌的收缩活动特征及变化规律.结果显示：不同浓度的乙酰胆碱和磷酸组织胺能增强小肠各段平滑肌的收缩频率与幅度,其幅值变化与用药前有显著性差异（P＜0.01） ,并呈剂量依赖性;而不同浓度的肾上腺素和阿托品则抑制小肠各段平滑肌（P＜0.01） .不同肠段对各种化学药物的作用存在着差异,一般十二指肠作用最强,空肠次之,回肠最差.     

黄芩苷对家兔离体子宫平滑肌的作用

目的:观察黄芩苷对家兔离体子宫平滑肌收缩的作用及其与Ca2+的关系.方法:制作常规离体家兔子宫平滑肌肌条,考察黄芩苷对子宫肌条反应的影响.结果:(1)黄芩苷(5-10mmol-L-1)剂量依赖抑制子宫平滑肌收缩;(2)黄芩苷对催产素及高K去极化液中Ca2+所致的离体子宫平滑肌收缩均呈剂量依赖性抑制;使CaC12累积量-效曲线非平行性右移,最大效应下降,呈非竞争性抑制;(3)且对子宫平滑肌依细胞内、外Ca2+两种收缩成分均呈抑制作用.结论:黄芩苷对家兔离体子宫平滑肌条的抑制作用,可能与其拮抗Ca2+有关.     

白介素6通过阻断L型钙离子通道活性抑制急性胰腺炎大鼠结肠纵行肌条收缩

本文旨在探讨白介素6 (interleukin 6, IL-6)对急性胰腺炎(acute pancreatitis, AP)大鼠结肠纵行肌条收缩的作用及其机制。用雨蛙肽和脂多糖联合诱导法制备AP大鼠模型,用生物机能实验系统观察IL-6对大鼠结肠纵行平滑肌条自发性收缩的影响,用ELISA检测血清IL-6的水平,用免疫组织化学染色法观察IL-6在结肠的表达分布,用全细胞膜片钳技术观察IL-6对结肠平滑肌细胞L型钙离子通道的影响。结果显示,与对照组相比,AP组大鼠结肠平滑肌条收缩幅度显著减小(P 0.05),收缩周期延长(P 0.05);IL-6可延长大鼠结肠平滑肌条收缩周期,但对肌条的自发性收缩幅度无影响。AP组大鼠血清IL-6浓度明显高于对照组,差异具有显著性(P 0.01);对照组大鼠结肠中IL-6表达较弥散,而在AP组结肠腺体、黏膜及黏膜下层中IL-6表达明显增强。IL-6可显著降低大鼠结肠平滑肌细胞L型钙离子通道的峰电流密度。以上结果提示,AP大鼠结肠运动减弱,其机制可能是表达上调的IL-6阻断结肠平滑肌细胞L型钙离子通道活性,进而抑制结肠纵行平滑肌收缩。     

RU486对早孕猕猴海马GR的影响

目的探讨早孕猕猴给予大剂量RU486 3天后海马糖皮质激素受体(GR)的表达变化.方法 15只早孕猕猴随机分为空白对照组、赋形剂组和RU486组.空白对照组不予任何处理,赋形剂组和RU486组分别鼻饲赋形剂和RU486 3天.应用单克隆抗体链菌素亲生物蛋白过氧化酶(SP)免疫组织化学方法观察海马GR的表达情况,并用电子计算机图象分析技术进行处理.结果 RU486组猕猴妊娠终止,该组的海马GR表达显著下降,与对照组的差异有显著性.空白对照组和赋形剂组猕猴妊娠没有终止,其海马GR表达无差异.结论 RU486可使早孕猕猴海马的GR表达下降,推测这可能是该药终止妊娠的中枢作用机理之一.     

Luteolytic action of RU486: Modulation of luteal 3β-hydroxysteroid dehydrogenase and 20α-hydroxysteroid dehydrogenase activities in late pregnant rats

The effect of the synthetic antiprogestin RU486 on luteal function in late pregnant rats was studied by evaluating the activities of the enzymes 3β-hydroxysteroid dehydrogenase (3β-HSD) and 20α-hydroxysteroid dehydrogenase (20α-HSD). RU486 (2 mg/kg) administered to rats on day 18 of pregnancy at 10.00 h induced preterm delivery 26.4 ± 0.35 h (n = 8) after treatment. Luteal 3β-HSD activity increased 24 and 34 h after RU486 injection, but a significant and progressive decrease started at 48 h with the maximal reduction 72 h after RU486 treatment, when compared with controls. Serum progesterone concentration decreased at the time of 3β-HSD activity reduction. Interestingly, 20α-HSD activity started to increase 58 h after RU486 injection. The administration of the cyclooxygenase inhibitor, diclofenac (1.3 mg/kg), on days 17–19 of pregnancy to RU486-treated rats, delayed abortion and the duration of delivery, and prevented the decrease in 3β-HSD and the increase in 20α-HSD activities observed 58 h after antiprogesterone treatment. RU486 administered intrabursally (1 μg per ovary) on day 20 (14.00–15.00 h) increased 3β-HSD and decreased 20α-HSD luteal activities at 18.00 h on day 21 of pregnancy, without modifying serum progesterone concentration, when compared with normal pregnant rats. In conclusion, the luteolytic process after preterm delivery induced by RU486 administration in late pregnant rats is characterized by a decrease in luteal 3β-HSD activity and circulating progesterone, which may trigger the increase in luteal 20α-HSD activity. Prostaglandins seems to be involved in the increase of 20α-HSD activity and therefore, in the demise of corpora lutea.     

Effect of the progesterone antagonist RU486 on human myometrial spontaneous contractility and PGI2 release.

We studied the effect of antiprogesterone RU 486 on spontaneous uterine contractility and PGI2 release with human myometrial strips superfused "in vitro". A decrease of PGI2 release into the superfusion medium was observed after 20 min superfusion. The inhibition was dose-dependent and reversible. After 20 min washing with tyrode medium without RU 486, the uterine strips recovered their initial rate of release. R5020, a progesterone agonist, did not affect PGI2 release nor dexamethasone and testosterone. Parallel to the decrease of PGI2 observed during RU 486 superfusion, the uterine spontaneous contraction frequency decreased, while the amplitude and duration of contractions increased. The alteration of uterine contractility was also rapid, dose-dependent and reversible. Modification of uterine strip spontaneous contractility, similar to those induced by RU 486, were also observed with superfusions of R5020 at concentrations as low as 10(-9)M, dexamethasone (10(-8)M), but not with superfusions of testosterone. These observations are not in favour of a progesterone-receptor mediated effect of RU 486 in our model. The mechanism of action may be related to the antiprogesterone specific structure i.e. the bulky substituent at the C-11 position. The RU 486 effect on uterine strip contractility, mimicked by other steroids, could point to a non-specific lipid/membrane interaction. However, the fact that testosterone did not affect motility, may indicate a possible specificity of steroids having a 3 oxo pregnene structure.     

Altered fetal pituitary-adrenal function in the ovine fetus treated with RU486 and meloxicam, an inhibitor of prostaglandin synthase-II

Term and preterm labor are associated with increased fetal hypothalamic-pituitary-adrenal (HPA) activation and synthesis of prostaglandins (PGs) generated through the increased expression of prostaglandin H synthase-II (PGHS-II) in the placenta. Inhibition of PGHS-II has been advocated as a means of producing uterine tocolysis, but the effects of such treatment on fetal endocrine functions have not been thoroughly examined. Because PGE(2) is known to activate the fetal HPA axis, we hypothesized that administration of meloxicam, a PGHS-II inhibitor, to sheep in induced labor would suppress fetal HPA function. Chronically catheterized pregnant ewes were treated with RU486, a progesterone receptor antagonist, to produce active labor, and then treated with either high-maintenance-dose meloxicam, graded-maintenance-dose meloxicam, or a saline infusion. Maternal uterine contraction frequency increased 24 h after the RU486 injection and the animals were in active labor by 48 +/- 4 h. RU486 injection led to increased concentrations of PGE(2), ACTH, and cortisol in the fetal circulation, and increased concentrations of 13,14 dihydro 15-ketoprostaglandin F(2 alpha) (PGFM) in the maternal circulation. Uterine activity was inhibited within 12 h of beginning meloxicam infusion at both infusion regimes. During meloxicam infusion there were significant decreases in fetal plasma PGE(2), ACTH, and cortisol concentrations, and PGFM concentrations in maternal plasma. In control animals, frequency of uterine contractions, maternal plasma PGFM, fetal plasma PGE(2), ACTH, and cortisol concentrations increased after RU486 administration, and continued to rise during saline infusion until delivery occurred. We conclude that RU486-provoked labor in sheep is associated with activation of fetal HPA function, and that this is attenuated during meloxicam treatment to a level considered compatible with pregnancy maintenance.     

New analogues of mifepristone with more dissociated antiprogesterone activities

Mifepristone (RU 486 or RU 38486) possesses strong antiprogesterone and antiglucocorticoid along with moderate antiandrogen properties, which would limit its use in some therapeutic applications. In a search for more dissociated derivatives, the hydroxy substituent and the propynyl group in position 17 of the RU 486 series was replaced by a spiroether group, which is known to induce specific affinity for the progestin receptor in steroid series. The substituents in the para position of the 11 beta-phenyl group, leading to the most potent derivatives in the RU 486 series, were retained. The new derivatives have been studied in vitro for their relative binding affinities (RBAs) for the steroid receptor and in vivo for their hormonal and antihormonal activities. The selected compounds, RU 46556 and RU 49295 display the following properties: in vitro, like RU 486, they show a strong RBA for the rabbit progestin receptor, but a much lower one for the rat thymus glucocorticoid receptor; in vivo they are about three times more active than RU 486 for inducing abortion in rats, but unlike the latter they are devoid of any antiglucocorticoid activity on the thymus weight in rats. These antiprogesterone effects have been confirmed on the deciduoma formation in rats and on the endometrial proliferation in rabbits. However, in contrast to RU 486 in the latter test, some progestomimetic activity has been observed. RU 46556 and RU 49295 are now under extensive pharmacological study.     

Effect of the progesterone antagonist RU486 on human myometrial spontaneous contractility and PGI2 release

We studied the effect of antiprogesterone RU 486 on spontaneous uterine contractility and PGI₂ release with human myometrial strips superfused “in vitro”. A decrease of PGI₂ release into the superfusion medium was observed after 20 min superfusion. The inhibition was dose-dependent and reversible. After 20 min washing with tyrode medium without RU 486, the uterine strips recovered their initial rate of release. R5020, a progesterone agonist, did not affect PGI₂ release nor dexamethasone and testosterone. Parallel to the decrease of PGI₂ observed during RU 486 superfusion, the uterine spontaneous contraction frequency decreased, while the amplitude and duration of contractions increased. The alteration of uterine contractility was also rapid, dose-dependent and reversible. Modifications of uterine strip spontaneous contractility, similar to those induced by RU 486, were also observed with superfusions of R5020 at concentrations as low as 10⁻⁹M, dexamethasone (10⁻⁸M), but not with superfusions of testosterone. These observations are not in favour of a progesterone-receptor mediated effect of RU 486 in our model. The mechanism of action may be related to the antiprogesterone specific structure i.e. the bulky substituent at the C-11 position. The RU 486 effect on uterine strip contractility, mimicked by other steroids, could point to a non-specific lipid/membrane interaction. However, the fact that testosterone did not affect motility, may indicate a possible specificity of steroids having a 3 oxo pregnene structure.